Dr. James Kreischer - Trichologist, MD Facebook ad: “Dermatologist Discovers Peptide Breakthrough That…”

About this ad

Meta Ad Library ID

1029298236345623

Platforms

Facebook, Instagram, Audience Network, Messenger and Threads

Relaunches

0

Niche

Supplements & Wellness

How we count

Ad text

If you're past the point of needing the basics explained — if you already know what DHT is, you've already tried finasteride and minoxidil, and you've already read everything on the forums — this is for you. Because at some point you've probably noticed the same pattern I noticed. The men who plateau on the standard protocol are not failing for hormonal reasons. Their bloodwork is fine. Their DHT is suppressed. Their dose is right. They plateau because the standard protocol only addresses one upstream input — the androgen — and ignores the structural event that actually ends a follicle: the loss of its stem-cell pool through the cutting of its anchoring collagen. Specifically, COL17A1 — Type-XVII collagen, the hemidesmosomal anchor that tethers hair-follicle stem cells to the basement membrane of the bulge. The mechanism is well-characterized. In a 2016 Science paper, Matsumura and colleagues showed that DNA damage in hair-follicle stem cells triggers proteolysis of COL17A1, which causes those stem cells to lose their niche anchorage, commit to an epidermal fate, and undergo transepidermal elimination — they are shed from the skin surface. The follicle miniaturizes stepwise and is ultimately lost. The authors explicitly tied the program to hair-follicle aging and noted its association with androgenetic alopecia. Forced maintenance of COL17A1 in the stem cells prevented the miniaturization. The downstream consequence is exactly the clinical picture: progressive miniaturization, and a bald scalp that becomes smooth and poreless because the follicular units have been emptied and effaced, not merely shrunk in place. The mechanism is straightforward. Oxidative and androgen-amplified stress drives DNA damage in the bulge stem cells. That damage upregulates proteases (neutrophil elastase and matrix metalloproteinases) that cleave COL17A1. Loss of the anchor releases the stem cell from its niche; it differentiates and is eliminated through the epidermis. With each lost stem cell, the follicle's regenerative capacity drops and the hair shaft it produces shrinks. Finasteride does not maintain COL17A1. Finasteride does not re-anchor stem cells already eliminated. Finasteride does not inhibit the proteases doing the cutting. It lowers one input to the stress, while the structural attrition continues under the prescription. This is the unaddressed second layer. And it maps cleanly to the symptoms men describe when they say their fin “plateaued” — and to the dread of watching a thinning zone go fully smooth. The fix is not another hormone modulator. The fix is to address the structural failure — reactivate the stem cells still resident in the niche, support the basement membrane and the anchoring complex, restore perifollicular perfusion, and quench the oxidative DNA damage driving the proteolysis. Four actives, at appropriate clinical concentrations, do this: sh-Polypeptide-1 and sh-Polypeptide-11. Recombinant signaling peptides that reactivate dormant follicle stem cells, restoring growth-phase signaling in the cells still anchored in the bulge. sh-Oligopeptide-2 and sh-Oligopeptide-10. Recombinant peptides that support keratinocyte and basement-membrane repair — reinforcing the niche structure where COL17A1 proteolysis has degraded stem-cell anchorage over years. Arginine. Substrate for endothelial NO synthase. Restores microvascular tone in the scalp and improves perifollicular perfusion of the dermal papilla and stem-cell niche. Botanical Anti-Inflammatory Extracts. Polyphenolic antioxidants that reduce the oxidative DNA damage and inflammatory load upstream of the proteases cleaving COL17A1. This isn't speculative. The COL17A1 program is one of the most cited findings in modern hair-follicle aging biology. The reason these actives aren't standard care is that they don't generate the recurring prescription revenue of the established treatments — not because they don't work. If you wanted to source these separately, expect roughly $260 a month for clinically meaningful versions of each. And expect to actually apply four products a day, in the right order, at the right concentration. Most men don't sustain that. FST-5 Peptide Complex (Richvell) is the version of this stack I've recommended to people who already know the space. Single serum. Five peptides plus arginine plus the botanical complex, at meaningful concentrations. One application a day. The brand is a peptide-research team that took over the older Keapers brand and rebuilt the product around the actual science. They don't sell in pharmacies. They don't mass-produce. They keep the stock tight. On the timeline, the inflection point is around four to eight weeks. Shedding declines and the lost hairs stop looking fine and fragile as more resident stem cells re-enter a productive cycle. Then the advancing smooth border stabilizes. Then, around the two-month mark, fine terminal regrowth appears at the margins. There's a 100-day money-back guarantee, which is the right window to actually evaluate the protocol on yourself. If you're past the basics and tired of being told the only path forward is another dose increase — and that the smooth zones are simply gone — this is the structural layer the standard protocol isn't addressing. Worth a fair test. 👉 https://richvell.com/pages/fst5

Where the ad sends people

richvell.com

Dermatologist Discovers Peptide Breakthrough That Reactivates Hair Growth Like You're 17 Again

Richvell FST-5 Peptide Complex helps support thicker-looking hair, reduced shedding, and a healthier scalp with advanced peptide-powered hair care.